Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography

Table 2

Current risk-adapted studies using interim PET in Hodgkin’s lymphoma.

Study	Group	Projected accrual	Timing of PET	Treatment
Limited disease:
RAPID trial [47]	UK NCRI	1600	After ABVD × 3	PET−, randomize to RT versus no further therapy
				PET+, further ABVD + RT
HD16 [48]	GHSG	1100	After ABVD × 2	Standard arm: RT regardless of PET
				Experimental: PET−, no further therapy
				Experimental: PET+, RT
H10 [49]	EORTC, GELA, IIL	1600	After ABVD × 2	Standard arm: complete ABVD + RT regardless of PET
				Experimental: PET−, complete ABVD (no RT)
				Experimental: PET+, BEACOPPesc then RT
Advanced disease:
HD18 [50]	GHSG	1500	After BEACOPPesc × 2	PET−, randomize to 2 versus 6 more cycles (no RT)
				PET+, randomize to BEACOPPesc with versus without rituximab^a
HD0607 [53]	GITIL	450	After ABVD × 2	PET−, complete ABVD; if still PET–, randomize to RT versus no RT
				PET+, randomize to BEACOPPesc with versus without rituximab^b
RATHL [51]	UK NCRI	1200	After ABVD × 2	PET−, randomize to ABVD versus AVD (no RT)
				PET+, BEACOPP-14 or BEACOPPesc
HD0801 [52]	IIL	300	After ABVD × 2	PET−, complete ABVD; if still PET–, randomize to RT versus no RT
				PET+, high-dose therapy with autologous BMT
S0816 [54]	SWOG intergroup	230	After ABVD × 2	PET−, further ABVD
				PET+, BEACOPPesc^c

ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BMT: blood or marrow transplantation; EORTC: European Organization for Research and Treatment of Cancer; esc, escalated; GELA: Groupe d'Étude des Lymphomes de l'Adulte; GHSG: German Hodgkin Study Group; GITIL: Gruppo Italiano Terapie Innovative Nei Linfomi; IIL: Intergruppo Italiano Linfomi; NCRI: National Cancer Research Institute; RATHL: response-adapted therapy in Hodgkin lymphoma; RT: radiation therapy; SWOG: Southwest Oncology Group.
^aRT restricted to residual ≥2.5 cm, PET+ sites on end-of-chemotherapy imaging.
^bIf PET− after 4 cycles of BEACOPPesc ± rituximab, changed to standard BEACOPP ± rituximab.
^cStandard BEACOPP if human immunodeficiency virus positive.